News Mersana stung by FDA hold on STING drug Death in ph1 trial casts a pall over GSK-backed project, licensed for $100m upfront last year.
Events Partner Content STING & TLR Targeting Therapies Summit Investigating the cGAS-STING and TLR pathways
News ASH: Blenrep ups survival by 42% in multiple myeloma trial GSK reveals the survival data that it reckons could return BCMA drug Blenrep to the forefront of multiple myeloma treatment.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
